Wells Fargo upgraded Tandem Diabetes to overweight from equal-weight and raised its price target to $55 from $45.
Analyst upgrades and target price changes can significantly influence investor sentiment and stock performance, particularly for companies in growth sectors like medical technology.
Analyst upgrades and target price changes can significantly influence investor sentiment and stock performance, particularly for companies in growth sectors like medical technology.
Pick the topics you care about. Get only what matters, on your cadence.
Market Quick Take – Bond yields hit 24-year highs, euro slides, and Nasdaq sets a record - 06 October 2026home.saxoTrading stocks, CFDs, spread betting, futures, and options involves a high level of risk and may not be suitable for all investors. Prices can move rapidly, and losses can occur quickly and exceed your expectations.
